Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.

Gastroenterology - 1 Jan 2007

Shiffman Mitchell L, Ghany Marc G, Morgan Timothy R, Wright Elizabeth C, Everson Gregory T, Lindsay Karen L, Lok Anna S F, Bonkovsky Herbert L, Di Bisceglie Adrian M, Lee William M, Dienstag Jules L, Gretch David R

Abstract excerpt

BACKGROUND & AIMS: Reducing the dose of peginterferon and/or ribavirin to <80% when treating chronic hepatitis C virus has been associated with a reduction in sustained virologic response (SVR). However, prior studies did not assess the impact of reducing the dose of peginterferon independent of ribavirin or differentiate between dose reduction or interrupting or prematurely discontinuing treatment. METHODS: Nine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Body Weight
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Liver Cirrhosis

Share to Polyethylene Glycols

Share to Recurrence

Share to Ribavirin

Source

Identifiers

PMID: 17241864
DOI: 10.1053/j.gastro.2006.11.011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.PMID 17241864Read ↗

Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment.Semantic proximity Read ↗

Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.Semantic proximity Read ↗

Sustained virological response based on the week 4 response in hepatitis C virus genotype 1 patients treated with peginterferons α-2a and α-2b, plus ribavirin.Semantic proximity Read ↗

Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients.Semantic proximity Read ↗

Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin.Semantic proximity Read ↗

Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin.Semantic proximity Read ↗

Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.Semantic proximity Read ↗

Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C.Semantic proximity Read ↗

Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.Semantic proximity Read ↗

Retreatment of patients who do not respond to initial therapy for chronic hepatitis C.Semantic proximity Read ↗

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.Semantic proximity Read ↗

Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.